Clinical Trial Update: Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of Disitamab Vedotin combined with Ivonescimab in cisplatin-ineligible muscle-invasive bladder cancer, with the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Bladder Cancer, Muscle-invasive Bladder Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING